Ocular Hypertension

The FDA accepted a new drug application for STN10117 for the treatment of glaucoma and ocular hypertension, Santen and Ube Industries announced in a press release.

Subjects treated with OTX-TIC demonstrated a mean reduction in IOP from baseline of 7 mm Hg to 11 mm Hg as early as 2 days after administration, according to interim phase 1 clinical trial results presented by Ocular Therapeutix.

The European Commission has granted marketing authorization for Roclanda to reduce IOP in adults with primary open-angle glaucoma or ocular hypertension, according to a press release from Aerie Pharmaceuticals.

An automated direct transscleral selective laser trabeculoplasty device demonstrated safety and efficacy in a first-in-human study, Michal Belkin, MD, said in a presentation at the virtual American Academy of Ophthalmology annual meeting.

In this Healio Video Perspective from the virtual AAO annual meeting, Michael R. Robinson, MD, discusses patient characteristics affecting long-term IOP-lowering effects after implantation of Durysta (bimatoprost implant, AbbVie).

Selective laser trabeculoplasty may be more effective and cheaper than eye drops when used as primary glaucoma management, Nathan Radcliffe, MD, said at the virtual OSN New York meeting.

During a most unexpected and challenging year, ophthalmic practices are looking for reasons to celebrate.

The most popular glaucoma articles on Healio/OSN in September include a current look at MIGS, the use of a nonvalved aqueous drainage implant and an update on a phase 2 trial.

Interim results from a phase 3b clinical trial in Europe showed Roclanda was non-inferior to Ganfort, according to a press release.

Aerpio Pharmaceuticals has completed enrollment in its phase 2 razuprotafib trial for patients with elevated IOP associated with open-angle glaucoma or ocular hypertension, according to a press release.